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Alloimmunization to the D antigen by a 
patient with weak D type 21
H. McGann and R.E. Wenk
Antibodies of apparent D specificity may be found in D+ pa-
tients. We report a D+, multi-transfused Caucasian woman 
with myelodysplasia who exhibited several alloantibodies. 
One antibody was a moderately strong (2+) anti-D that per-
sisted for 9 months, until the woman died. Molecular analy-
sis of the patient’s RHD gene identified the rare weak D type 
21 (938C>T) allele. D alloantibodies do not occur in patients 
with most weak D types, but some patients with a weak D 
phenotype, including those with type 21, can produce an-
tibodies to nonself epitopes of the wild-type D antigen. 
Immunohematology 2010;26:27–29.
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A ntibodies with D specificity are unusual in D+ pa-tients. Alloantibodies to D may be (1) passively transfused in donor plasma products, (2) passively 
transferred but actively produced by lymphocytes carried 
in transplanted organs, and (3) actively produced by an al-
loimmunized patient. Autoantibodies to D may be warm- or 
cold-reactive antibodies with a preference for D+ RBCs or 
may be antibodies to LW that mimic anti-D specificity.1
 In practice, the combination of clinical, serologic, and 
molecular investigations helps to determine why a D+ pa-
tient has anti-D. Establishing the source of a D+ patient’s 
alloantibody or autoantibody with D specificity is important 
in deciding whether D+ or D– units should be transfused to 
optimize donor RBC survival (Table 1).
 In this case report, we describe a woman whose RBCs 
were strongly D+ at the phenotypic level, but had an RHD 
genotype consistent with weak D, and an alloanti-D.
Case Report
 A 72-year-old, gravida 3, Caucasian woman with myel-
odysplasia and pancytopenia was transferred from another 
hospital, where in 6 months of treatment, she had received 
an unknown number of platelet transfusions, but no RBC 
transfusions.
 In our hospital and before any RBC transfusion, the 
patient’s RBCs serologically typed as D+ (4+) by tube ag-
glutination at immediate spin phase, using a monoclonal-
polyclonal blended anti-D (Ortho Clinical Diagnostics Co., 
Raritan, NJ). During a disease course of 13 months, the 
patient received 37 apheresis-processed platelet units and 
108 leukocyte-reduced units of RBCs, which produced al-
loimmunization to K, E, and Cw. After 9 months, her serum 
also demonstrated a 2+ anti-D in a gel-based, antibody de-
tection system (Micro Typing Systems, Inc., Ortho Clinical 
Diagnostics, Pompano Beach, FL). The initial DAT (tube, 
anti-IgG) and all but one subsequent DAT were negative as 
was the auto-control. On the one occasion, the DAT became 
weakly positive in a mixed-field reaction. Acid eluates pre-
pared from the patient’s RBCs contained only anti-E. There 
was no history of organ transplantation or administration 
of a plasma product that might contain anti-D. The anti-D 
persisted throughout the patient’s course. Blood samples 
were collected and referred for RHD and RHCE gene analyses.
 Although continued transfusions with D– blood were 
prescribed, the patient refused all further medical treat-
ment. Her myelodysplasia progressed to early acute leuke-
mia before she expired at home.
Molecular Test Results
 Molecular tests were performed at the Molecular Red 
Cell and Platelet Testing Laboratory of the American Red 
Cross, Penn-Jersey Region, and the University of Penn-
sylvania DNA Sequencing Facility, both in Philadelphia, 
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Pennsylvania. The patient was found to be heterozygous 
for RHD. No changes associated with any of the known 
partial D phenotypes were identified. A change (938C>T) 
was identified that is associated with weak D type 21 that is 
predicted to encode an intracellular amino acid change of 
Pro313Leu. The patient’s RH genotype could be interpreted 
to be RHD*weak D type 21, RHCE*Ce/RHCE*ce. 
Discussion 
 Initially, the finding of anti-D in a D+ patient was puz-
zling and the several causes listed in Table 1 were consid-
ered. Patients whose anti-D was passively transferred in 
plasma products (IVIG, RhIG, etc.) or whose serum anti-
bodies were produced by a donor’s passenger lymphocytes 
may require D– RBCs until the acquired anti-D has weak-
ened, usually in a matter of weeks to months.
 Passive anti-D, however, was ruled out by history. Be-
fore hospital admission at our institution, the patient had 
been transfused only with apheresis platelets, but she had 
not been transfused with plasma or cellular products from 
D– donors, nor had she been infused with IVIG or injected 
with RhIG. Persistence of the anti-D was further evidence 
that the anti-D did not involve passive immunization.
 The transfer of passenger lymphocytes could be ex-
cluded by history as well. The patient had never received a 
transplant. Passenger lymphocytes are alloantibody-secreting 
B cells that are carried in a transplanted donor organ to a 
recipient. An anti-D produced by passenger lymphocytes 
arises in the donor by alloimmunization to the D antigen 
before transplantation. Donor lymphocytes continue to 
manufacture detectable anti-D for about 3 months after 
transplantation.
 Many patients with autoimmune hemolytic anemia and 
mimicking antibodies to Rh antigens are treated medically 
and transfusion is avoided altogether. In other patients, 
transfusion can be delayed until the concentration of an-
tibodies is reduced by medical treatment. Many mimicking 
warm autoantibodies have apparent Rh specificity, especially 
anti-e. Only rare D+ patients will possess warm autoan-
tibodies that mimic anti-D. If a patient with autoantibodies 
requires transfusion, antigen-negative donor RBCs may be 
preferable because they may survive longer than antigen-
positive RBCs.2
 Antibodies to LW are almost always autoantibodies; 
those that are less potent appear to have anti-D specific-
ity because the number of D antigen sites per RBC corre-
lates with the number of LW antigen sites.3 Thus, D– RBCs, 
which have fewer LW antigen sites than D+ RBCs, may not 
be agglutinated by an anti-LW. However, anti-LW may be 
distinguished from anti-D by its failure to agglutinate RBCs 
treated with DTT. If transfusion is required for a patient 
with autoanti-LW, D– RBCs are preferable to D+ RBCs pro-
viding such a patient is c+.
 Patient autoantibodies, including anti-LW, are often 
transient, but our patient’s anti-D persisted for 4 months 
at constant serologic strength (2+ by the IgG gel test). 
Alloantibodies to Rh antigens are often durable (85%). 
Negative DATs and absence of RBC agglutination in auto-
control tests also indicated the presence of D alloantibody.
 LW alloantibodies, which can mimic anti-D, arise 
only in very rare individuals whose RBCs are LW(a–b–) 
or LW(a–b+). Neither autoantibodies nor alloantibodies 
to LW were specifically evaluated in the patient described 
here.
 Alloantibodies to the D antigen occur in people who are 
known to lack one or more epitopes of D (partial D pheno-
type). On the other hand, anti-D alloimmune responses in 
patients with other weak D types are unusual because their 
RBCs do not appear to lack D epitopes when tested with a 
standard battery of anti-D monoclonal reagents.4
 Suspicion that the patient had been alloimmunized to 
D antigen was raised by the serologic finding of negative 
DATs and the antibody’s persistence. In addition, people 
who carry variants of the D antigen that are detectable only 
by molecular means are capable of producing antibodies 
to wild-type protein. In the present case, finding a variant 
RHD gene supported the clinical and serologic evidence of 
D alloimmunization.
 Historically, some D+ individuals who made anti-D were 
initially considered to express a weak D phenotype (first 
termed “DU”) when tested with human polyclonal reagents. 
Serologic evidence of alloimmunization to D in a D+ person 
included a negative DAT, a serum antibody, and, for some 
partial D phenotypes, the patient’s RBCs also expressed a 
low-prevalence Rh antigen.5 A D+ patient with alloanti-D 
was thought to lack part(s) of the D antigen, i.e., a “partial 
D” type. A person with a partial D phenotype would only 
produce antibody to those epitopes of the D antigen missing 
from his or her own RBCs. Investigative use of monoclonal 
antibody revealed many epitopes of the D antigen and sup-
ported the concept that partial D types lacked one or more 
epitopes of their D antigen. The monoclonal antibodies also 
extended the identification and classification of the various 
partial D types initially defined by polyclonal anti-D.
 Many individuals, however, were found to have RBCs 
that agglutinated poorly with common anti-D reagents, but 
demonstrated the presence of all known epitopes. These D+ 
RBCs were called “weak D” in preference to DU.  Weak D 
RBCs expressed fewer D molecules per RBC, a finding that 
accounted for their weak agglutination with reagent anti-
bodies. Theoretically, individuals who carried these weak 
D types should not be able to develop alloantibodies to D. 
However, it is virtually impossible to distinguish a person 
with a weak D phenotype from a person with a weak par-
tial D phenotype by serologic tests; only the production 
of alloanti-D will reveal someone to have a weak partial D 
phenotype.
 When molecular analysis became available, the RHD 
(and RHCE) gene(s) revealed far more extensive and com-
plex polymorphisms than were evident by serologic meth-
ods. Weakly agglutinating D serotypes could be related to 
point mutations, nonsense mutations, deletions, and tandem 
H. McGann and R.E. Wenk
IMMUNOHEMATOLOGY, Volume 26, Number 1, 2010 29
Anti-D in weak D type 21
rearrangements in the RHD and RHCE DNA. The cause of 
weak RBC agglutination was confirmed to be an absence of 
epitopes in partial D types, a decreased number of protein 
molecules in weak D types, or both. In addition, partial D 
phenotypes are expressions of genotypes that encode for 
changes in the amino acids on the outer surface of the RBC 
where the D protein loops outside the RBC membrane. 
Patients whose RBCs express partial D types are often im-
munized to D+ RBCs by transfusion or pregnancy. On the 
other hand, genotypes that encode weak D phenotypes are 
predicted to result in intracellular or intramembranous 
changes in amino acids that, in theory, express all epitopes 
of D so that patients whose RBCs express weak D types 
are not expected to produce anti-D after immunization by 
transfusion or pregnancy. Theory is partly supported by 
evidence—the most common weak D variants (types 1–3), 
which constitute 70 to 90 percent of all weak D variants, do 
not produce alloanti-D.6 
 Molecular examination of the various partial and weak 
D types indicated that many serologic phenotypes had more 
than one basis, but did not suggest that new epitopes could 
be identified.7 However, serologic evidence suggested oth-
erwise. Anti-D has been found in some weak D patients 
whose D protein is predicted by their DNA sequences to 
have altered intramembranous and intracellular amino ac-
ids of the D protein. Thus, some weak D molecular alleles 
contain missense mutations that not only reduce the num-
ber of antigens per RBC and cause weak RBC agglutination 
by reagent antibodies but also cause a loss of D epitopes 
and produce changes in the three-dimensional antigenic 
structure of the D protein.
 The case presented here indicates that the rare weak 
D type 21 is an allelic variant whose patient-carriers are 
susceptible to transfusion alloimmunization by wild-type D 
antigen. Weak D type 21 is the result of a point mutation 
that alters an amino acid thought to be in an intracellular 
region of the D protein.8 The rare allele was first discovered 
in one individual during investigation of 270 known weak 
D samples in people from northern Germany,9 and there 
has been one subsequent independent observation of it in 
Austria.10 In both cases, the allele has been found on the 
same chromosome (cis) as a RHCE*Ce allele in the haplo-
type RHDweak D type 2-RHCE*Ce. The Pro313Leu change in the 
translated D protein is in its tenth intracellular helix, and all 
37 tested epitopes of the D antigen appear to be present.9 As 
expected, the number of D antigen sites per RBC is reduced 
(5.2 × 103) when compared with the normal number (104 
to 2.5 × 104) of sites.11 This antigen density is the highest 
among all known weak D alleles. The high density probably 
accounts for the patient’s 4+ serotype and explains why she 
was not identified as a weak D carrier.
Summary
 We evaluated a patient with a strongly expressed D an-
tigen with a posttransfusion antibody to the D antigen. The 
antibody had clinical and serologic characteristics of an 
alloantibody. After RHD and RHCE genotyping, the patient 
was found to have the RHDweakD type 21RHCE*Ce/RHCE*ce 
genotype (R1
weak D type 21r phenotype). Although most patients 
with a weak D phenotype do not produce alloanti-D, pa-
tients who carry the rare weak D type 21 in the absence of a 
normal RHD allele appear susceptible to the production of 
D alloantibodies.
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